Greenwich LifeSciences, Inc. (GLSI) is a clinical-stage biopharmaceutical company focused primarily on developing immunotherapy treatments designed to prevent breast cancer recurrences after surgery. Founded to advance proprietary immunotherapies like GP2, the company advanced through various early clinical trials and public market listings, capturing significant investor attention based on ongoing phase-three clinical trial progress and immunotherapeutic cancer research milestones.